ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

COG Cambridge Cognition Holdings Plc

45.00
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 45.00 44.00 46.00 45.00 45.00 45.00 37,202 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 13.52M -3.51M -0.1007 -4.47 15.68M

Cambridge Cognition Holdings PLC Total Voting Rights and Block Listing Return

02/04/2024 4:20pm

RNS Regulatory News


RNS Number : 0298J
Cambridge Cognition Holdings PLC
02 April 2024
 

2 April 2024

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Total Voting Rights and Block Listing Return

 

 

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, announces that pursuant to its block admission facility, details of which were announced on 21 March 2023, it has recently issued 189,263 new ordinary shares in the Company in satisfaction of the exercise of employee share options. Accordingly, as at 31 March 2024 the Company has 35,149,372 ordinary shares in issue.

 

There are no shares held in treasury therefore the total number of voting rights in the Company is 35,149372. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in Cambridge Cognition under the FCA's Disclosure and Transparency Rules.

 

Block Listing Return

 

The Company also makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

 

 

Name of applicant:

Cambridge Cognition Holdings plc

Name of scheme:

Share Options

Period of return:

From:

1 October 2023

To:

31 March 2024

Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:

1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on 23 March 2023

Balance of unallotted securities under scheme(s) from previous return:

762,855 ordinary shares

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:  Number of securities issued/allotted under scheme(s) during period:

296,539 ordinary shares

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

466,316 ordinary shares

 

Name of contact:

Stephen Symonds

Telephone number of contact:

+44 (0)1223 810700

 

 

Enquiries:

 

Cambridge Cognition Holdings plc 

Matthew Stork, Chief Executive Officer 

Stephen Symonds, Chief Financial Officer 

Tel: 012 2381 0700 

press@camcog.com 

 

Panmure Gordon (UK) Limited (NOMAD and Joint Broker) 

Freddy Crossley / Emma Earl  

Rupert Dearden 

 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

 

Dowgate Capital Limited (Joint Broker) 

David Poutney / James Serjeant 

 

Tel: 020 3903 7715 

 

 

Hudson Sandler (Financial PR and IR) 

Dan de Belder / Hattie Dreyfus 

 

Tel: 020 7796 4133 

cog@hudsonsandler.com

 


 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRSSWFIEELSEFL

1 Year Cambridge Cognition Chart

1 Year Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

Your Recent History

Delayed Upgrade Clock